NPCE
Neuropace Inc Health Care Surgical & Medical Instruments & Apparatus Russell 3000
$12.30Close
$413.0MMarket cap
$9.40 – $19.2952-week range
Nov 3, 2026Next report
Highlights
Cautions
- Not in an uptrend 2 of 8 trend conditions
- Lagging the market RS 29 · weaker than 71% of stocks over 12 months
- Far from its high 36% below its 52-week high
- Results soon Nov 3, 2026, in 2 days
- Financial distress Altman Z″ in the distress zone
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
36%
1wk
down 4.7%
price change
1mo
down 10.6%
price change
12-month return
up 25%
market up 11% ·
its own up 11%
F-score
4 / 9
Weak
Altman Z
-3.16
Elevated risk
P/E
—
price / earnings
PEG
—
P/E / EPS growth
P/B
21.7×
price / book
Earnings yield
down 3.6%
EBIT / enterprise value
Cheaper than
12%
of the market · expensive
Revenue growth
up 25%
year on year
EPS growth
—
latest quarter
Sales growth
up 17%
latest quarter · +19 pts
ROE
down 159%
return on equity
Free cash margin
down 11%
-$11.3M FCF
D/E
3.09
long-term debt / equity
Net debt / EBITDA
—
Interest cover
—EBIT / interest
Piotroski tests
- not yet profitable on its assets
- operating cash flow is negative
- took on more long-term debt
- short-term liquidity weakened
- issued more shares
- profitability improving
- profits backed by cash
- gross margin widened
- assets working harder
Repair signals
- Gross margin 73.9% → 77.2%
Trade setup
ATR%
4.7%
$0.57 a day · 2×ATR $11.15
RS
29 / 99
vs the universe
Trend
2 / 8
trend template
Relative volume
0.7×
vs 50-day average
Up/down volume
1.24
50 sessions
Implied move
—
no option chain · report Nov 3, 2026
Trend template · 2 of 8
- 150-day average above the 200-day: passes
- At least 30% above the 52-week low: passes
Screen verdict
Did not qualify for any screen.
Warning signs
- Bankruptcy model reads distressed The Altman score sits inside the range historically associated with financial distress. It is used here only to exclude, never to rank, and it is a statistical band rather than a prediction about this company.
- Shareholders diluted The share count rose 11.4% over the year, from 30m to 34m shares. Each existing share owns a smaller fraction of the company than it did a year ago.
Last reported
Aug 11, 2026
Results reaction
Aug 11, 2026-2% vs market2 sessions after results
Financials
- Gross 77%
- Net -21%
- Free cash -11%
- Cash
- Long-term debt
| FY2020Dec 31, 2020 | FY2021Dec 31, 2021 | FY2022Dec 31, 2022 | FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $41.1M | $45.2M | $45.5M | $65.4M | $79.9M | $100.0M |
| Gross margin | 74% | 74% | 71% | 74% | 74% | 77% |
| Operating income | -$13.1M | -$23.7M | -$40.8M | -$27.2M | -$21.7M | -$16.3M |
| Net income | -$24.3M | -$36.1M | -$47.1M | -$33.0M | -$27.1M | -$21.5M |
| Net margin | -59% | -80% | -103% | -50% | -34% | -21% |
| Earnings per share | -$118.97 | -$2.17 | -$1.91 | -$1.27 | -$0.93 | -$0.66 |
| Free cash flow | -$21.7M | -$25.0M | -$37.5M | -$19.9M | -$18.3M | -$11.3M |
| Free cash margin | -53% | -55% | -82% | -30% | -23% | -11% |
| Cash | $26.4M | $19.2M | $6.6M | $18.1M | $13.4M | $21.7M |
| Long-term debt | $50.8M | $49.8M | $52.9M | $57.0M | $59.5M | $58.9M |
| Shareholders' equity | -$147.8M | $73.5M | $34.8M | $20.7M | $8.0M | $19.0M |
| Shares outstanding | 314.10k | 24.45m | 25.05m | 27.82m | 30.15m | 33.57m |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Aug 11, 2026 | Quarterly ↗ | Jun 30, 2026 | 42d |
| May 12, 2026 | Quarterly ↗ | Mar 31, 2026 | 42d |
| Mar 3, 2026 | Annual ↗ | Dec 31, 2025 | 62d |
| Nov 4, 2025 | Quarterly ↗ | Sep 30, 2025 | 35d |
| Aug 12, 2025 | Quarterly ↗ | Jun 30, 2025 | 43d |
| May 13, 2025 | Quarterly ↗ | Mar 31, 2025 | 43d |
| Mar 4, 2025 | Annual ↗ | Dec 31, 2024 | 63d |
| Nov 12, 2024 | Quarterly ↗ | Sep 30, 2024 | 43d |
| Aug 13, 2024 | Quarterly ↗ | Jun 30, 2024 | 44d |
| May 8, 2024 | Quarterly ↗ | Mar 31, 2024 | 38d |
| Mar 5, 2024 | Annual ↗ | Dec 31, 2023 | 65d |
| Nov 6, 2023 | Quarterly ↗ | Sep 30, 2023 | 37d |
Current reports
| Filed | Disclosed |
|---|---|
| Aug 11, 2026 | Results ↗ |
| Jul 28, 2026 | Regulation FD ↗ |
| Jun 8, 2026 | Shareholder vote ↗ |
| May 12, 2026 | Results ↗ |
| Mar 3, 2026 | Results ↗ |
| Nov 4, 2025 | Results ↗ |
| Aug 12, 2025 | Results ↗ |
| Jun 24, 2025 | Director or officer change · Regulation FD ↗ |
| Jun 12, 2025 | Shareholder vote ↗ |
| Jun 4, 2025 | Material agreement · Agreement ended · New obligation · Regulation FD ↗ |
| May 27, 2025 | Regulation FD · Other events ↗ |
| May 13, 2025 | Results ↗ |